Dipeptidylpeptidase-4 inhibitors (gliptins) focus on drug-drug interactions

AJ Scheen - Clinical pharmacokinetics, 2010 - Springer
Patients with type 2 diabetes mellitus (T2DM) are generally treated with many
pharmacological compounds and are exposed to a high risk of drug-drug interactions …

Heterocyclic compounds as dipeptidyl peptidase-IV inhibitors with special emphasis on oxadiazoles as potent anti-diabetic agents

BD Mohammad, MS Baig, N Bhandari, FA Siddiqui… - Molecules, 2022 - mdpi.com
Dipeptidyl peptidase-IV (DPP-IV) inhibitors, often known as gliptins, have been used to treat
type 2 diabetes mellitus (T2DM). They may be combined with other medications as an …

Tolerability of dipeptidyl peptidase-4 inhibitors: a review

KR Richard, JS Shelburne, JK Kirk - Clinical therapeutics, 2011 - Elsevier
BACKGROUND: Oral glucose-lowering agents are used to treat patients with type 2
diabetes mellitus (T2DM). Most patients require multiple agents to maintain glycemic targets …

DPP-4 inhibitors: focus on safety

SH Tella, MS Rendell - Expert opinion on drug safety, 2015 - Taylor & Francis
Introduction: Dipeptidyl peptidase inhibitors (DPP-4-i) are highly selective inhibitors of the
enzyme DPP-4. They act by increasing levels of incretin hormones, which have potent …

Novel univariate spectrophotometric determination of the recently released solid dosage form comprising dapagliflozin and saxagliptin via factorized response spectra …

HM Lotfy, D Mohamed, MS Elshahed - Spectrochimica Acta Part A …, 2019 - Elsevier
Dapagliflozin (DPF) and saxagliptin (SXG) are currently co-formulated in a tablet dosage
form which is prescribed to improve glycemic control. The absorption spectra of DPF and …

Rapid generation of novel benzoic acid–based xanthine derivatives as highly potent, selective and long acting DPP-4 inhibitors: scaffold-hopping and prodrug study

Q Li, L Meng, S Zhou, X Deng, N Wang, Y Ji… - European Journal of …, 2019 - Elsevier
A series of novel xanthine derivatives 2a-l incorporating benzoic acid moieties were rapidly
generated by using strategy of scaffold-hopping from our previously reported scaffold uracil …

Design, synthesis and biological evaluation of Imidazo [1, 2‐a] pyridine derivatives as novel DPP‐4 inhibitors

Q Li, M Zhou, L Han, Q Cao, X Wang… - Chemical biology & …, 2015 - Wiley Online Library
A new series of DPP‐4 inhibitors with imidazo [1, 2‐a] pyridine scaffold were designed by
exploiting scaffold hopping strategy and docking study. Based on docking binding model …

Discovery of triazole-based uracil derivatives bearing amide moieties as novel dipeptidyl peptidase-IV inhibitors

X Deng, L Han, J Zhou, H Zhang, Q Li - Bioorganic Chemistry, 2017 - Elsevier
Abstract Dipeptidyl peptidase-IV (DPP-4) is a validated target for T2DM treatment. We
previously reported a novel series of triazole-based uracil derivatives bearing aliphatic …

Identification of novel uracil derivatives incorporating benzoic acid moieties as highly potent Dipeptidyl Peptidase-IV inhibitors

J Huang, X Deng, S Zhou, N Wang, Y Qin… - Bioorganic & Medicinal …, 2019 - Elsevier
Abstract Dipeptidyl Peptidase-IV (DPP-4) is a validated therapeutic target for type 2
diabetes. Aiming to interact with both residues Try629 and Lys554 in S 2′ site, a series of …

Fast and effective identification of the bioactive compounds and their targets from medicinal plants via computational chemical biology approach

S Zhang, W Lu, X Liu, Y Diao, F Bai, L Wang… - …, 2011 - pubs.rsc.org
The potential drug target database (PDTD) was searched by the TarFisDock server, a
reverse docking approach, to identify putative targets for a collection of 19 natural products …